PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer

Innos, 2019, Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016, Acta Oncol., 1–8 Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2018;29:iv192-iv237. Gandhi, 2018, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, New England J Med, 378, 2078, 10.1056/NEJMoa1801005 Rodrigues, 2011, Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline, Pract Radiat Oncol., 1, 60, 10.1016/j.prro.2011.01.005 Gomez, 2019, Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study, J Clin Oncol., 37, 1558, 10.1200/JCO.19.00201 Ren, 2019, Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB), Onco Targets Therapy, 12, 4235, 10.2147/OTT.S199176 Camidge, 2019, Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC, Nat Rev Clin Oncol, 16, 341, 10.1038/s41571-019-0173-9 Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, New England J Med, 375, 1823, 10.1056/NEJMoa1606774 Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7 Pawelczyk, 2019, Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers, Int J Mol Sci, 20, 10.3390/ijms20040824 Sheng, 2016, Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer, Sci Rep, 6, 20090, 10.1038/srep20090 Rojko, 2018, Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients, J Cancer Res Clin Oncol, 144, 1219, 10.1007/s00432-018-2642-4 Guo, 2019, Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer, J Immunother., 42, 215, 10.1097/CJI.0000000000000275 Shin, 2019, Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer, Cancer Res Treat, 51, 1086, 10.4143/crt.2018.537 Gong, 2018, Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination, J ImmunoTher Cancer, 6, 46, 10.1186/s40425-018-0361-7 Shen, 2017, Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway, Oncotarget, 8, 80506, 10.18632/oncotarget.19193 Herter-Sprie, 2016, Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer, JCI insight, 1, 10.1172/jci.insight.87415 Gong, 2017, Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer, J Thoracic Oncol, 12, 1085, 10.1016/j.jtho.2017.04.014 Takamori, 2018, Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review, Clin Lung Cancer, 19, 12, 10.1016/j.cllc.2017.06.015 Shaverdian, 2017, Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, 18, 895, 10.1016/S1470-2045(17)30380-7 McLaughlin, 2016, Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA oncology., 2, 46, 10.1001/jamaoncol.2015.3638